After DES implantation, DAPT for 1 y vs. ≤6 mo increased major bleeding in patients with high baseline bleeding risk

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Clinical Trials

Background:

• Dual antiplatelet therapy (DAPT) is standard after drug-eluting stent (DES) implantation.
• Optimal DAPT duration remains debated, especially in patients stratified by bleeding and ischemic risk.

Purpose of the Study:

• To evaluate the risk-benefit profile of 1-year DAPT versus shorter durations in patients undergoing DES implantation.
• To assess the impact of bleeding and ischemic risk stratification on DAPT outcomes.

Main Methods:

• Retrospective analysis of a large patient cohort undergoing DES implantation.
• Stratification of patients based on established bleeding and ischemic risk scores.
• Comparison of clinical outcomes (ischemic events, bleeding events) between different DAPT durations.

Main Results:

• One-year DAPT demonstrated a favorable net clinical benefit in the overall population.
• Patients with high ischemic risk and low bleeding risk particularly benefited from 1-year DAPT.
• Shorter DAPT durations were associated with increased ischemic events in high-risk patients.

Conclusions:

• A 1-year DAPT duration appears to be a safe and effective strategy after DES implantation.
• Risk stratification is crucial for tailoring DAPT duration to individual patient profiles.
• Personalized DAPT strategies can optimize outcomes by balancing ischemic and bleeding risks.